Clinical Trial Update: Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study of pacritinib in myelofibrosis patients previously treated with ruxolitinib has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: CTI BioPharma | Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2022-06-01